TECH 240920 70.00C (TECH240920C70000) Stock Options, News & Quotes

US OptionsDetailed Quotes

TECH240920C70000

Watchlist

3.80
-1.90-33.33%

15min DelayClose Sep 3 16:00 ET

3.80High3.80Low

Intraday

5D
Daily

News

Some Investors May Be Willing To Look Past Bio-Techne's (NASDAQ:TECH) Soft Earnings
Simply Wall StAug 30 06:45 ET
Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Moomoo NewsAug 30 03:32 ET · Ratings
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
TipRanksAug 30 02:57 ET · Ratings
ScaleReady Announces the Inaugural G-Rex Grant Has Been Awarded to Stanford Medicine Laboratory for Cell and Gene Medicine
newsfilter.ioAug 27 07:00 ET
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
PR NewswireAug 26 07:00 ET
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Simply Wall StAug 25 10:13 ET

Comments

Trytosaveabit

May 22 06:21

Update

$Regulus Therapeutics (RGLS.US)$ $Bio-Techne (TECH.US)$ Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Moomoo AI

Dec 28, 2023 05:17

Despite Bio-Techne's high P/E ratio, the lower forecast growth potentially overvalues it. Investors may risk a share price decline due to weak earnings outlook, posing a risk for those holding onto shares.